Omeros (OMER) Misses Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/16/2026
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Oil slips as Saudi Arabia offers more crude via Oman
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- U.S. Commerce Department to sell up to 9.9M GlobalFoundries shares
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- AI chip sell-off overblown: Zero GPU slowdown after Anthropic essay, analyst says
- Wall Street ends lower as oil spikes and the benchmark Treasury yield breaches 5%
Omeros Corporation Reports First Quarter 2016 Financial Results
May 10, 2016 7:20 AM EDT-- Conference Call Today at 9:00 a.m. ET --
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the first quarter of 2016, which include:
1Q 2016 revenues were $7.4 million, an 11% increase over 4Q 2015. Net loss in 1Q was $20.5 million, or $0.54 per share, which included $4.7 million ($0.12 per share) of non-cash... MoreLeonard M. Blum Joins Omeros to Lead Business and Commercial Activities
May 10, 2016 7:05 AM EDTSEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced the hiring of Leonard Blum as chief business and commercial officer. Mr. Blum is leading the companys sales, marketing, commercial strategy and planning, and business development, including for OMIDRIA® (phenylephrine and ketorolac injection) 1% / 0.3% and the companys growing pipeline of development-stage programs.
Mr. Blum brings over 28 years of executive and management experience in... More
